Ultragenyx Shares Fall 6% After Plans to Cut Staff, End Drug Projects
Ultragenyx said it would reduce its workforce and discontinue certain drug development programs. Shares fell 6% to $15.67 in after-hours trading Tuesday.
By Katherine HamiltonUltragenyx Pharmaceutical shares fell after the company said it was cutting its workforce and discontinuing certain drug developments.The stock slid 6% to $15.67 in after-hours trading Tuesday. Through the prior close, shares were down 30% this year.The biopharmaceutical compan…